BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI PD-1 INDUCED THYROID DYSFUNCTION

Abstract Objective: To characterize anti-programmed cell death 1 (PD-1) induced thyroid immune related adverse events (irAEs) in metastatic melanoma patients treated at our institution and to identify risk factors associated with their development. Methods: We reviewed the files of 154 patients with metastatic melanoma treated with PD-1 inhibitors at a single institution from November 1, 2011 to February 28, 2017. The association of thyroid irAEs within 120 days post-treatment initiation with age, gender, melanoma characteristics, treatment protocol, and baseline TSH was examined. Results: Overall, 42.4% developed thyroid dysfunction following treatment, including 20.2% (20/99) subclinical thyroid dysfunction, 13.1% (13/99) overt hypothyroidism and 9.1% (9/99) overt hyperthyroidism. Of those that developed overt hyperthyroidism, 8 progressed to overt hypothyroidism, consistent with thyroiditis. Age, gender, melanoma characteristics or treatment protocol did not modify the risk of developing thyroid irAEs....